discoveri
angiotensiniconvert
enzym
pro
renin
receptor
renew
interest
physiolog
reninangiotensin
system
ra
ma
counterregulatori
axi
balanc
vasoconstrict
prolif
fibrot
proinflammatori
effect
aceangiotensin
axi
pro
renin
receptor
system
show
angiotensindepend
function
relat
increas
gener
angiotensin
angiotensinindepend
aspect
relat
intracellular
signal
activ
inhibit
ace
renin
core
ra
regul
aim
review
discuss
biochemistri
biolog
function
ace
renin
within
beyond
ra
thu
provid
perspect
futur
bioactiv
natur
plant
andor
food
resourc
relat
three
proteas
angiotensin
inhibiteur
de
lenzym
de
convers
inhibiteur
de
lenzym
de
convers
ii
de
la
la
de
lenzym
de
convers
de
langiotensin
et
un
la
est
une
dan
la
de
la
physiologi
du
au
sein
de
lax
inhibiteur
de
lenzym
de
convers
de
langiotensin
contrebal
leffet
vasoconstricteur
fibros
et
proinflammatoir
de
lax
aceangiotensin
le
la
une
fonction
angiotensin
laugment
de
la
product
dangiotensin
et
un
aspect
de
langiotensin
aux
signaux
intracellulair
lactiv
de
et
linhibit
de
lace
de
la
ont
comm
au
centr
de
la
du
lobjet
de
cett
revu
est
de
discut
le
fonction
biochimiqu
et
biologiqu
de
lace
de
et
de
la
au
sein
et
du
et
ainsi
de
propos
une
perspect
de
dagent
actif
extrait
de
plant
naturel
ou
daliment
produit
ce
troi
elsevi
masson
sa
tou
droit
reninangiotensin
system
ra
endocrin
also
paracrin
intracrin
system
mammal
intravascular
ra
play
key
role
maintain
blood
pressur
homeostasi
fluid
salt
balanc
tissu
local
ra
involv
physiolog
patholog
process
tissu
growth
remodel
develop
inflamm
classic
ra
substrat
angiotensinogen
agt
releas
circul
liver
degrad
enzym
renin
origin
kidney
gener
inact
angiotensin
ang
decapeptid
come
contact
angiotensiniconvert
enzym
ace
endotheli
surfac
blood
vessel
ctermin
dipeptid
cleav
give
rise
angiotensin
ii
ang
ii
main
effector
molecul
ra
interact
specif
receptor
particularli
type
receptor
ang
ii
stimul
wide
varieti
signal
pathway
heart
blood
vessel
kidney
adipos
tissu
pancrea
brain
initi
physiolog
pathophysiolog
effect
attribut
ra
due
function
directli
gener
main
effector
ang
ii
ace
togeth
classic
axi
aceang
core
ra
studi
sinc
discoveri
homologu
ace
known
angiotensiniconvert
enzym
clone
two
independ
research
group
evid
indic
neg
regul
activ
ra
degrad
ang
ii
heptapeptid
ang
moreov
ma
receptor
g
proteincoupl
receptor
result
ang
counterbal
cardiovascular
effect
ang
ii
oppos
mani
receptormedi
action
axi
ma
becom
focu
intens
research
regard
ra
discoveri
pro
renin
receptor
p
rr
introduct
renin
inhibitor
also
brought
pro
renin
back
spotlight
far
straightforward
cascad
contain
one
substrat
agt
two
proteas
renin
ace
two
peptid
ang
ang
ii
one
receptor
ra
current
consist
sever
axe
upstream
downstream
classic
cascad
includ
two
dozen
peptidas
nearli
dozen
ang
fragment
least
six
differ
receptor
review
three
critic
proteas
ace
renin
within
beyond
ra
thu
intend
find
new
connect
natur
plant
andor
food
resourc
ra
occurr
gene
encod
structur
ace
ace
ec
monomer
glycoprotein
distribut
mani
tissu
biolog
fluid
two
isoform
ace
human
somat
ace
sace
germin
ace
gace
somat
ace
found
mani
type
endotheli
epitheli
cell
germin
ace
testicular
ace
present
exclus
germin
cell
male
testi
although
ace
type
integr
membran
protein
also
releas
solubl
enzym
extracellular
fluid
plasma
semin
cerebrospin
fluid
follow
posttransl
proteolyt
cleavag
membran
protein
sheddas
secretas
somat
ace
gace
encod
singl
gene
contain
exon
promot
sace
situat
flank
region
first
exon
wherea
gace
within
intron
result
differ
length
two
isoform
longer
sace
kda
transcrib
exon
exon
exclud
exon
wherea
shorter
gace
kda
transcrib
exon
exon
exon
encod
uniqu
sequenc
nterminu
gace
wherea
downstream
exon
encod
common
sequenc
isozym
somat
ace
gace
consist
hydrophil
ctermin
cytoplasm
domain
hydrophob
transmembran
domain
anchor
protein
membran
ntermin
ectodomain
fig
heavili
glycosyl
mannos
galactos
fructos
nacetylneuramin
acid
nacetylglucosamin
ectodomain
sace
divid
two
similar
domain
n
domain
c
domain
encod
homolog
exon
respect
domain
contain
activ
hisgluxxhi
hexxh
sequenc
somat
ace
known
metallopeptidas
two
homolog
activ
site
impli
gene
duplic
event
evolut
except
uniqu
sequenc
constitut
nterminu
gace
ident
ctermin
half
sace
due
cleavag
membranebound
residu
ace
secretas
solubl
circul
ace
lack
transmembran
portion
cytosol
domain
threedimension
xray
crystallograph
structur
deglycosyl
truncat
version
gace
c
domain
sace
reveal
preponder
zinc
ion
two
chlorid
ion
incorpor
deep
narrow
channel
separ
molecul
two
subdomain
activ
site
locat
toward
bottom
channel
ntermin
lid
top
molecul
appear
allow
small
peptid
substrat
access
activ
site
cleft
fact
structur
bear
littl
similar
carboxypeptidas
famili
initi
drug
develop
ace
inhibitor
base
instead
resembl
rat
neurolysin
famili
pyrococcu
furiosu
carboxypeptidas
famili
despit
share
littl
sequenc
similar
two
protein
corradi
et
al
report
crystal
structur
n
domain
sace
similarli
ellipsoid
shape
central
groov
divid
two
subdomain
one
contain
ntermin
region
cover
central
bind
caviti
structur
reveal
differ
activ
site
contain
one
chlorid
ion
equival
chlorid
ii
gace
threedimension
structur
c
domain
base
gace
n
domain
provid
opportun
design
domainselect
ace
inhibitor
may
exhibit
new
pharmacolog
profil
accord
catalyt
mechan
critic
amino
acid
residu
involv
peptidas
classifi
four
major
type
serin
cystein
aspart
metallo
ace
famili
metallopeptidas
e
gluzincin
two
histidin
residu
function
motif
hexxh
third
distant
glutam
posit
residu
toward
cterminu
ligand
zinc
cofactor
activ
water
molecul
complex
zn
serv
nucleophil
attack
carbonyl
group
target
peptid
bond
activ
ace
also
chlorid
depend
chlorid
primarili
activ
activ
site
ace
enhanc
bind
substrat
activ
domain
ace
display
differ
sensit
chlorid
activ
activ
c
domain
sace
depend
highli
chlorid
ion
concentr
inact
absenc
wherea
n
domain
complet
activ
rel
low
concentr
anion
still
activ
absenc
chlorid
germin
ace
depend
chlorid
lesser
extent
compar
c
domain
sace
cushman
cheung
report
optim
vitro
ace
activ
rabbit
rung
aceton
extract
presenc
mm
nacl
ph
two
activ
domain
sace
also
subtli
differ
substrat
specif
hydrolyz
bradykinin
almost
equal
c
domain
activ
site
hydrolyz
ang
substrat
p
hippurylhisleu
effici
n
domain
activ
site
preferenti
hydrolyz
ang
lutein
hormonereleas
hormon
lhrh
haemoregulatori
peptid
nacetylserasplyspro
acsdkp
alzheim
amyloid
fuch
et
al
prove
ctermin
catalyt
domain
main
site
ang
cleavag
mice
differenti
catalyt
specif
might
due
subtl
variat
substratespecif
amino
acid
chlorideinduc
conform
alter
activ
site
ace
act
exopeptidas
cleav
dipeptid
free
ctermini
two
typic
substrat
ang
bradykinin
certain
substrat
cholecystokinin
substrat
p
lhrh
amid
ctermini
ace
display
exopeptidas
activ
also
act
endopeptidas
promin
exampl
endopeptidas
activ
ace
hydrolyz
synthet
peptid
four
fragment
peptid
other
correspond
product
hydrolysi
thu
ace
might
gener
impact
metabol
biolog
activ
peptid
previous
recogn
two
substrat
use
often
measur
ace
activ
inhibit
vitro
hippurylhisleu
n
acryloyl
lphenylalanylglycylglycin
fapgg
ntermini
block
substrat
two
termini
block
develop
ace
origin
isol
hypertensinconvert
enzym
ra
ace
cleav
decapeptid
ang
aspargvaltyrilehisprophehisleu
octapeptid
ang
ii
remov
ctermin
dipeptid
hisleu
ra
overact
ang
ii
exert
harm
effect
primarili
via
receptor
wherea
receptor
may
oppos
counterbal
effect
mediat
receptor
exert
protect
action
ang
ii
potent
vasoconstrictor
stimul
releas
aldosteron
antidiuret
hormon
vasopressin
increas
retent
sodium
water
effect
act
directli
concert
rais
blood
pressur
nonapeptid
deriv
ang
prevent
infarctionrel
noninfarctionrel
cardiac
injuri
disord
hisleu
cleav
peptid
ace
produc
ang
iii
vasoconstrict
activ
ang
ii
ang
iii
exert
effect
principl
similar
manner
ang
ii
may
equal
even
import
mediat
releas
vasopressin
ace
also
degrad
ang
ang
degrad
peptid
inact
ang
fig
addit
ace
also
term
kininas
ii
inactiv
vasodil
bradykinin
argproproglypheserprophearg
kallidin
lysbradykinin
kallikreinkinin
system
cleav
ctermin
dipeptid
phearg
ace
eventu
cleav
primari
metabolit
bradykinin
shorter
fragment
bradykinin
ang
ii
aldosteron
ace
may
also
implic
impair
nitric
oxid
bioavail
cell
oxid
stress
augment
gener
reactiv
oxygen
speci
peroxynitrit
abil
hydrolyz
neuropeptid
enkephalin
substrat
p
neurotensin
lhrh
ace
may
involv
function
brain
nervou
system
ace
may
affect
digest
system
hydrolyz
peptid
hormon
cholecystokinin
gastrin
vivo
experi
conduct
azizi
et
al
prove
acut
ace
inhibit
could
increas
level
natur
stem
cell
regul
acsdkp
plasma
acsdkp
substanti
inhibit
cell
cycl
entri
normal
haematopoiet
stem
cell
protect
haemopoiesi
damag
caus
cycleact
cytotox
agent
acsdkp
also
inhibit
prolifer
hepatocyt
lymphocyt
stimul
angiogenesi
vivo
vivo
antifibrot
effect
ace
inhibit
partial
mediat
acsdkp
ace
may
also
affect
suscept
alzheim
diseas
degrad
prevent
accumul
amyloid
plaqu
vivo
brain
amyloid
precursor
protein
swedish
mutat
transgen
mice
ace
convert
degrad
chronic
inhibit
ace
captopril
enhanc
predomin
deposit
howev
inhibit
brain
ace
activ
inject
mice
perindopril
amelior
cognit
impair
may
therefor
benefici
effect
alzheim
diseas
well
hypertens
use
assum
mechanist
analog
zinc
metallopeptidas
plu
knowledg
sever
snakevenom
peptid
potenti
action
bradykinin
inhibit
ace
effort
undertaken
develop
orallyact
peptid
analogu
potenti
use
treatment
hypertens
first
compound
captopril
analogu
alapro
sequenc
sulphydryl
strong
chelat
group
zinc
ion
advers
effect
caus
mercaptocontain
penicillamin
prompt
design
nonsulphydryl
ace
inhibitor
result
two
activ
inhibitor
enalaprilat
lisinopril
essenti
tripeptid
analogu
zinccoordin
carboxyl
group
phenylalanin
occupi
groov
enzym
lisinopril
lysin
analogu
enalaprilat
hydrophil
greater
affin
enalaprilat
later
compound
variat
first
three
inhibitor
differ
resid
function
bind
activ
site
zinc
pocket
addit
phosphon
keton
also
use
chelat
current
ace
inhibitor
market
wide
use
firstlin
therapi
cardiovascular
diseas
includ
hypertens
heart
failur
heart
attack
left
ventricular
dysfunct
accord
function
moieti
divid
three
type
thiol
captopril
carboxyl
benazepril
enalapril
lisinopril
moexipril
perindopril
quinapril
ramipril
trandolapril
phosphat
fosinopril
ace
inhibitor
administr
clinic
ethylest
prodrug
good
bioavail
inact
right
convert
activ
diacid
molecul
vivo
esteras
drug
class
ace
inhibitor
effect
rel
low
incid
side
effect
well
toler
common
side
effect
ace
inhibitor
dri
cough
appear
patient
may
result
discontinu
treatment
anoth
seriou
problem
angioedema
affect
patient
lifethreaten
two
side
effect
gener
attribut
alter
concentr
bradykinin
use
ace
inhibitor
second
third
trimest
pregnanc
contraind
associ
increas
risk
foetopathi
group
condit
includ
oligohydramnio
intrauterin
growth
retard
hypocalvaria
renal
dysplasia
anuria
renal
failur
death
exposur
ace
inhibitor
first
trimest
pregnanc
may
place
infant
increas
risk
major
congenit
malform
initi
drug
develop
clinic
ace
inhibitor
base
assumpt
activ
site
relat
carboxypeptidas
organ
remov
dipeptid
rather
singl
amino
acid
cterminu
substrat
known
sace
two
activ
site
neither
resembl
carboxypeptidas
site
ident
clinic
ace
inhibitor
howev
show
littl
discrimin
two
activ
site
ang
hydrolyz
predominantli
c
domain
sace
vivo
bradykinin
hydrolyz
activ
site
therefor
c
domainselect
inhibitor
would
allow
degrad
bradykinin
n
domain
degrad
could
enough
prevent
accumul
excess
bradykinin
observ
attack
angioedema
c
domainselect
inhibit
could
possibl
result
special
control
blood
pressur
fewer
vasodilatorrel
advers
effect
structureact
studi
prove
group
substitut
involv
phenyl
ring
carbon
chain
sulphonyl
propionyl
moieti
captopril
essenti
better
activ
toward
c
domain
ace
increas
evid
n
domain
sace
respons
vivo
degrad
natur
haemoregulatori
hormon
acsdkp
n
domainselect
inhibit
might
open
novel
therapeut
area
two
phosphin
tetrapeptid
found
highli
select
inhibitor
c
n
domain
sace
respect
avail
threedimension
structur
c
n
domain
sace
make
structurebas
design
activ
sitespecif
inhibitor
possibl
ec
also
type
transmembran
glycoprotein
express
recogn
ubiquit
appear
suscept
cleavag
releas
catalyt
activ
ectodomain
disintegrin
metalloproteas
also
known
tumour
necrosi
factoralpha
cleavag
enzym
tace
major
proteas
solubl
shed
phorbol
ester
ionomycin
endotoxin
proinflammatori
cytokin
tumour
necrosi
factoralpha
also
acut
induc
ectodomain
releas
calmodulin
bind
site
identifi
cytoplasm
tail
calmodulin
inhibitor
prove
increas
shed
cleavag
site
resid
amino
acid
near
predict
transmembran
domain
residu
ly
ectodomain
play
import
role
dictat
ectodomain
shed
amino
acid
encod
exon
share
sequenc
ident
n
c
domain
sace
also
belong
famili
metalloproteas
consist
singl
activ
site
domain
sequenc
comparison
close
resembl
n
domain
c
domain
sace
fig
addit
conserv
zinc
metallopeptidas
consensu
sequenc
hexxh
amino
acid
conserv
glutam
residu
residu
ctermin
second
histidin
zinc
motif
serv
third
zinc
ligand
threedimension
structur
truncat
extracellular
region
human
show
activ
site
domain
residu
divid
two
subdomain
ii
form
two
side
long
deep
cleft
connect
floor
activ
site
cleft
promin
deepli
recess
shield
proteolyt
activ
site
common
structur
featur
proteas
avoid
hydrolysi
correctli
fold
function
protein
zinc
coordin
glu
one
water
molecul
subdomain
near
bottom
wherea
chlorid
ion
coordin
arg
trp
ly
subdomain
ii
transmembran
ctermin
domain
share
sequenc
ident
collectrin
fig
noncatalyt
protein
shown
critic
role
amino
acid
reabsorpt
kidney
pancreat
beta
cell
prolifer
possibl
insulin
exocytosi
unlik
sace
gace
primarili
dipeptidylcarboxypeptidas
function
predominantli
monocarboxypeptidas
substrat
prefer
hydrolysi
prolin
hydrophob
basic
ctermin
residu
like
carboxypeptidas
action
model
differ
activ
structur
latter
hxxe
zincbind
motif
third
ligand
histidin
posit
residu
toward
cterminu
effici
cleav
singl
residu
phenylalanin
ang
ii
gener
ang
higher
catalyt
effici
convers
ang
ang
remov
ctermin
leucin
residu
fig
substrat
high
catalyt
effici
dynorphin
arg
identifi
residu
critic
substrat
select
activ
also
regul
chlorid
ion
propos
chlorid
bind
induc
subtl
chang
conform
activ
site
either
facilit
hinder
substrat
bind
substrat
ang
activ
increas
increas
cl
plateau
reach
approxim
mm
cl
substrat
ang
ii
increas
activ
observ
cl
increas
mm
increas
cl
decreas
activ
plateau
reach
mm
cl
activ
mm
cl
even
lower
absenc
cl
mm
consequ
increas
cl
mm
physiolog
concentr
human
plasma
increas
ang
decreas
ang
ii
cleavag
effect
local
concentr
ang
ii
kidney
high
level
express
extracellular
chlorid
ion
level
fluctuat
thu
vivo
cl
sensit
may
serv
homeostat
regulatori
mechan
activ
unaffect
inhibitor
ace
captopril
lisinopril
enalaprilat
carboxypeptidas
benzylsuccin
potato
carboxypeptidas
inhibitor
major
function
counterregul
ace
activ
reduc
ang
ii
bioavail
increas
ang
format
result
play
crucial
role
maintain
balanc
two
axe
ma
aceang
ra
chronic
sustain
imbal
may
lead
pathophysiolog
cardiovascular
renal
pulmonari
central
nervou
system
studi
shown
overexpress
recombin
treatment
attenu
hypertens
anim
model
human
strong
associ
polymorph
hypertens
han
chines
addit
ang
ii
system
may
regul
blood
pressur
peptid
system
bradykinin
andor
apelin
gene
deliveri
ace
infus
also
benefici
effect
atherosclerosi
wherea
defici
accentu
vascular
atherosclerosi
inflamm
anim
model
regard
heart
function
null
mice
display
impair
cardiac
contractil
loss
wildtyp
mice
acceler
advers
ventricular
remodel
potenti
ang
ii
effect
mean
receptor
ang
interact
ma
receptor
improv
atrial
tachyarrhythmia
myocardi
perform
cardiac
model
surviv
rodent
heart
failur
model
human
gene
variant
might
involv
modul
left
ventricular
mass
men
solubl
activ
increas
patient
heart
failur
correl
diseas
sever
exert
cardioprotect
action
delet
gene
mice
lead
develop
glomerulosclerosi
increas
albuminuria
treatment
inhibitor
worsen
renal
damag
streptozotocininduc
diabet
mice
chronic
treatment
ang
improv
renal
endotheli
dysfunct
via
ma
receptor
apolipoprotein
edefici
mice
increas
level
endogen
nitric
oxid
wherea
genet
delet
ma
receptor
mice
lead
reduct
urin
volum
sodium
retent
microalbuminuria
reduc
renal
blood
flow
associ
upregul
receptor
transform
growth
factorbeta
messeng
ribonucl
acid
evid
indic
protect
role
ma
renal
function
also
shown
regul
cardiovascular
function
brain
region
overexpress
rostral
ventrolater
medulla
reduc
high
blood
pressur
heart
rate
spontan
hypertens
rat
shr
nucleu
tractu
solitariu
shr
gene
transfer
improv
baroreceptor
heart
rate
reflex
mous
subforn
organ
overexpress
inhibit
receptor
express
prevent
ang
iimedi
pressor
drink
respons
addit
ma
exert
cerebroprotect
function
ischaem
stroke
rodent
model
exert
host
action
cardiopulmonari
system
includ
prevent
endotheli
dysfunct
reduct
pulmonari
oxid
stress
attenu
vascular
impair
antiinflammatori
effect
anticardiac
remodel
effect
properti
respons
protect
role
pulmonari
arteri
hypertens
structurebas
drug
screen
identifi
two
activ
xanthenon
ethylamino
hydroxymethyl
sulphonyloxi
xnt
resorcinolnaphthalein
xnt
hydrogen
bond
residu
ly
tyr
gli
resorcinolnaphthalein
involv
three
hydrogen
bond
residu
gln
gln
gli
xnt
resorcinolnaphthalein
modul
activ
possibl
two
mechan
logic
close
conform
enzym
allow
substrat
activ
site
presenc
compound
free
enzym
may
shift
open
form
effect
increas
activ
coeffici
enzym
altern
product
releas
ratelimit
step
turnov
activ
may
enhanc
presenc
compound
enzymeproduct
complex
empti
quickli
becom
avail
start
anoth
cycl
xnt
resorcinolnaphthalein
enhanc
vitro
activ
dosedepend
manner
show
signific
effect
ace
activ
administr
xnt
shr
result
decreas
blood
pressur
improv
cardiac
function
revers
myocardi
perivascular
renal
fibrosi
protect
role
xnt
hypertensioninduc
cardiac
fibrosi
associ
activ
increas
ang
inhibit
extracellular
signalregul
kinas
furthermor
activ
xnt
attenu
thrombu
format
reduc
platelet
attach
vessel
xnt
also
prevent
pulmonari
vascular
remodel
right
ventricular
hypertrophi
fibrosi
rat
model
monocrotalineinduc
pulmonari
hypertens
develop
xnt
pursu
translat
vasoprotect
concept
effect
cardiovascular
therapi
diminazin
acetur
small
molecul
antiprotozo
agent
share
structur
similar
xnt
recent
demonstr
potent
activ
decreas
mean
arteri
pressur
myocardi
fibrosi
shr
intracerebroventricular
infus
diminazin
acetur
prior
follow
middl
cerebr
arteri
occlus
significantli
attenu
cerebr
infarct
size
neurolog
deficit
rat
model
data
suggest
diminazin
acetur
may
serv
lead
compound
discoveri
next
gener
drug
treatment
cardiovascular
diseas
hypertens
interestingli
peptidaseindepend
action
also
elucid
identifi
essenti
receptor
coronaviru
cov
caus
sever
acut
respiratori
syndrom
sar
spike
protein
sarscov
attach
viru
cellular
receptor
bind
domain
spike
protein
mediat
interact
interact
lead
endocytosi
viru
particl
intern
induc
fusion
viru
host
cell
establish
sarscov
infect
releas
viral
rna
cytoplasm
spike
protein
sarscov
also
induc
tacedepend
shed
ectodomain
involv
cytoplasm
domain
cellular
tace
cytoplasm
tail
promot
viral
entri
infect
observ
indic
shed
caus
cellular
signal
may
attribut
sarscovinduc
tissu
damag
inhibitor
n
aziridineethanamin
identifi
effect
block
sarscov
spike
proteinmedi
cell
fusion
sarscov
receptor
function
independ
catalyt
activ
ang
ii
degrad
ang
ii
degrad
still
import
lung
protect
sar
pathogenesi
consequ
longterm
activ
must
determin
effect
activ
immun
compet
anim
vulner
sarscov
infect
must
test
molecul
readi
preclin
trial
also
receptor
human
coronaviru
discov
netherland
shown
global
distribut
addit
due
high
homolog
collectrin
transmembran
bind
b
amino
acid
transport
contribut
absorpt
neutral
amino
acid
anim
intestin
thu
may
involv
multipl
biolog
function
renin
ec
key
enzym
ra
sinc
discoveri
year
ago
impress
quantiti
inform
renin
compil
gener
accept
activ
renin
found
circul
mammal
almost
exclus
origin
kidney
addit
system
renin
number
extraren
tissu
express
renin
part
local
tissuespecif
rass
within
kidney
renin
predominantli
produc
juxtaglomerular
cell
pro
renin
gene
transcript
cell
control
sever
mechan
among
cyclic
adenosin
monophosph
camp
protein
kinas
acamp
respons
element
bind
protein
stimulatori
calciumprotein
kinas
c
inhibitori
cascad
employ
physiolog
cue
wherea
signal
transduc
activ
transcript
nuclear
factor
b
transcript
factor
inhibitori
member
nuclear
receptor
superfamili
probabl
becom
relev
patholog
situat
prorenin
store
vesicl
activ
renin
releas
upon
demand
releas
renin
control
intracellular
camp
stimulatori
ca
inhibitori
cyclic
guanosin
monophosph
signal
pathway
meanwhil
great
number
intraren
gener
system
act
factor
identifi
control
renin
secret
directli
level
reninproduc
cell
activ
camp
ca
signal
pathway
renin
aspartyl
proteas
typic
structur
made
two
lobe
cleft
lobe
contain
activ
site
character
two
catalyt
aspart
residu
renin
highli
specif
enzym
one
known
substrat
agt
prorenin
inact
precursor
renin
addit
main
organ
kidney
tissu
brain
adren
gland
submandibular
gland
gland
reproduct
system
adipos
tissu
also
abl
secret
prorenin
surround
milieu
plasma
contrast
renin
prorenin
releas
constitut
renin
prorenin
level
usual
well
correl
physiopatholog
circumst
pregnanc
diabet
prorenin
level
exceed
far
renin
prorenin
proseg
amino
acid
residu
attach
nterminu
matur
renin
proseg
fold
activ
site
cleft
matur
renin
prevent
catalyt
interact
agt
proreninrenin
convers
occur
kidney
renin
releas
juxtaglomerular
cell
sever
enzym
includ
proconvertas
cathepsin
b
propos
respons
irrevers
cleavag
proseg
prorenin
form
matur
renin
revers
nonproteolyt
activ
prorenin
may
also
occur
acid
ph
andor
low
temperatur
prorenin
capabl
undergo
conform
chang
involv
unfold
proseg
enzymat
cleft
nonproteolyticallyactiv
prorenin
fulli
enzymat
activ
physiolog
condit
approxim
plasma
prorenin
open
form
also
display
enzymat
activ
tradit
assumpt
renin
enzym
respons
cleavag
agt
prorenin
inact
proenzym
challeng
clone
human
p
rr
p
rr
singl
transmembranedomain
protein
amino
acid
larg
unglycosyl
highli
hydrophob
ntermin
domain
respons
renin
prorenin
bind
short
cytoplasm
tail
amino
acid
involv
intracellular
signal
p
rr
first
identifi
cultur
human
mesangi
cell
bound
well
renin
prorenin
k
nanomolar
rang
bind
prorenin
induc
conform
chang
molecul
increas
enzymat
activ
virtual
zero
valu
similar
activ
renin
solut
without
proteolyt
remov
proseg
two
region
human
prorenin
segment
name
fkr
gate
access
specif
antibodi
loosen
activ
site
cleft
flkr
handl
protrud
pentamer
segment
identifi
crucial
nonproteolyt
activ
renin
bound
p
rr
display
increas
catalyt
effici
agt
convers
ang
compar
free
renin
addit
angdepend
function
cell
surfac
relat
increas
catalyt
activ
receptorbound
pro
renin
renin
activ
activ
prorenin
increas
activ
renin
lead
format
ang
agt
p
rr
system
also
angindepend
intracellular
effect
necessarili
relat
ra
patholog
condit
like
high
blood
pressur
upregul
receptor
wherea
elev
pro
renin
concentr
downregul
receptor
via
transloc
transcript
factor
promyelot
zinc
finger
protein
nucleu
angindepend
signal
pathway
prorenininduc
activ
mitogenactiv
protein
kinas
subsequ
phosphoryl
heat
shock
protein
result
actin
polymer
pro
renininduc
activ
extracellular
signalregul
kinas
signal
cascad
lead
intracellular
express
profibrot
gene
give
rise
synthesi
transform
growth
plasminogen
activ
collagen
fibronectin
effect
potenti
increas
cardiac
renal
hypertrophi
fibrosi
discoveri
p
rr
confirm
hypothesi
renin
also
hormon
suggest
block
p
rr
may
new
target
renal
cardiac
endorgan
protect
addit
growth
factor
ii
receptor
bind
renin
prorenin
high
affin
believ
serv
clearanc
receptor
reninprorenin
intracellular
reninbind
protein
also
clone
found
inhibitor
renin
activ
delet
affect
neither
blood
pressur
plasma
renin
discoveri
receptor
p
rr
antagonist
design
base
idea
proseg
contain
handl
region
bind
receptor
allow
prorenin
becom
catalyt
activ
nonproteolyt
manner
antagonist
also
known
hand
region
peptid
hrp
consist
amino
acid
nh
rillkkmpsvcooh
resembl
handl
region
llkk
rat
prorenin
proseg
thu
competit
bind
p
rr
decoy
peptid
inhibit
receptormedi
activ
prorenin
treatment
hrp
diabet
mice
rat
decreas
renal
content
ang
ii
inhibit
develop
nephropathi
without
affect
hyperglycaemia
strokepron
shr
continu
subcutan
administr
hrp
inhibit
activ
tissu
ra
without
affect
circul
ra
arteri
pressur
significantli
attenu
develop
progress
proteinuria
glomerulosclerosi
cardiac
fibrosi
infus
hrp
human
p
rr
transgen
rat
significantli
inhibit
develop
glomerulosclerosi
proteinuria
mitogenactiv
protein
kinas
activ
transform
growth
express
kidney
futur
research
abl
determin
degre
benefici
vivo
effect
hrp
due
prorenin
blockad
relat
interfer
renin
bind
ra
decoy
effect
hrp
howev
confirm
research
group
ace
inhibitor
receptor
blocker
arb
proven
effect
therapeut
agent
treatment
cvd
howev
ace
inhibitor
arb
lead
substanti
compensatori
rise
circul
activ
renin
ang
peptid
may
eventu
limit
therapeut
potenti
moreov
increas
ang
seen
ace
inhibitor
subsequ
convert
ang
ii
nonac
pathway
mediat
chymas
chymotrypsinlik
anggener
enzym
addit
side
effect
ace
inhibitor
cough
angioedema
metaanalysi
random
control
trial
suggest
arb
associ
modestli
increas
risk
new
cancer
diagnosi
although
conclus
exact
risk
cancer
associ
particular
drug
drawn
base
studi
unit
state
food
drug
administr
conduct
review
assess
possibl
link
use
arb
cancer
therefor
direct
renin
inhibit
may
altern
pharmacolog
approach
ra
inhibit
renin
ratelimit
step
ra
concept
block
ra
origin
inhibit
renin
exist
least
year
firstgener
renin
inhibitor
peptid
analogu
agt
secondgener
compound
peptidomimet
agent
dipeptid
transitionst
analogu
inhibitor
activ
site
renin
inhibitor
limit
clinic
use
due
poor
metabol
stabil
oral
bioavail
short
durat
action
weak
antihypertens
activ
high
cost
synthesi
combin
molecular
model
xray
crystallograph
analysi
activ
site
renin
led
develop
aliskiren
new
nonpeptid
lowmolecularweight
orallyact
renin
inhibitor
aliskiren
high
bind
affin
renin
appear
bind
hydrophob
pocket
larg
distinct
subpocket
extend
site
toward
hydrophob
core
enzym
aliskiren
potent
competit
inhibitor
renin
poorli
inhibit
relat
aspart
peptidas
show
effect
cytochrom
isoenzym
activ
bound
extens
blood
protein
therefor
low
potenti
drug
interact
compar
earlier
renin
inhibitor
aliskiren
resist
intestin
degrad
possess
significantli
improv
oral
bioavail
termin
halflif
rang
hour
make
suitabl
oncedaili
dose
aliskiren
monotherapi
display
antihypertens
efficaci
similar
superior
firstlin
antihypertens
drug
safeti
toler
profil
similar
arb
combin
variou
antihypertens
agent
aliskiren
exhibit
synergist
effect
aliskiren
approv
regulatori
bodi
europ
unit
state
use
alon
agent
treatment
hypertens
recent
studi
show
aliskiren
treatment
also
markedli
increas
plasma
concentr
pro
renin
patient
fail
inhibit
noncatalyt
effect
pro
renin
pharmaceut
compani
novarti
report
addit
aliskiren
standard
therapi
patient
recov
heart
attack
provid
anticip
effect
limit
advers
chang
heart
left
ventricl
decemb
novarti
announc
earli
termin
aliskiren
trial
type
diabet
use
cardioren
endpoint
altitud
advis
aliskiren
use
combin
ace
inhibitor
arb
patient
diabet
studi
conduct
type
diabet
patient
high
risk
fatal
nonfat
cardiovascular
renal
event
aliskiren
mg
given
addit
ace
inhibitor
arb
overse
data
monitor
committe
conclud
studi
patient
unlik
benefit
aliskiren
higher
incid
advers
event
relat
nonfat
stroke
renal
complic
hyperkalaemia
hypotens
highrisk
popul
month
combin
therapi
wwwnovartiscom
aliskiren
shown
safe
antihypertens
patientyear
data
howev
seen
ongo
telmisartan
alon
combin
ramipril
global
endpoint
trial
ontarget
combin
telmisartan
arb
ramipril
ace
inhibitor
associ
advers
event
without
increas
benefit
patient
vascular
diseas
highrisk
diabet
without
heart
failur
combin
multipl
safe
drug
class
may
longer
promis
strategi
last
decad
number
foodderiv
compound
shown
vitro
ace
inhibitori
activ
display
signific
antihypertens
activ
rat
human
among
compound
foodderiv
ace
inhibitori
peptid
wide
studi
quantit
structureact
relationship
studi
indic
potent
ace
inhibitori
dipeptid
larg
hydrophob
amino
acid
cterminu
nonpolar
amino
acid
possibl
posit
charg
amino
acid
nterminu
tripeptid
favour
residu
cterminu
aromat
amino
acid
hydrophob
amino
acid
prefer
nterminu
posit
charg
amino
acid
prefer
middl
posit
vitro
halfmaxim
inhibitori
concentr
ic
valu
foodderiv
ace
inhibitori
peptid
higher
synthet
captopril
higher
vivo
activ
would
expect
vitro
activ
suggest
foodderiv
peptid
might
act
via
differ
antihypertens
mechan
possess
higher
affin
tissu
slowli
elimin
synthet
captopril
two
lactotripeptid
vpp
ipp
success
commerci
data
van
mierlo
et
al
howev
support
blood
pressurelow
effect
two
tripeptid
caucasian
given
discrep
vivo
vitro
result
investig
vivo
clinic
antihypertens
effect
mechan
foodderiv
ace
inhibitor
necessari
three
dipeptid
ir
kf
ef
pea
protein
hydrol
identifi
inhibit
renin
activ
vitro
oleic
acid
linol
acid
isol
rice
cereal
also
vitro
renin
inhibitori
activ
seri
studi
shown
saponin
differ
foodplant
sourc
primarili
soybean
inhibit
vitro
renin
activ
among
oral
administ
soybean
saponin
lead
reduct
blood
pressur
shr
direct
evid
saponin
suppress
plasma
renin
activ
vivo
still
lack
experi
requir
investig
biochem
biolog
properti
plantfoodderiv
nonpeptid
relat
renin
inhibit
signific
conceptu
progress
made
last
year
lead
us
conclud
could
serv
new
direct
improv
therapeut
cardiovascular
diseas
compar
ace
inhibitor
therapi
endogen
regul
ra
target
would
produc
vasoprotectiveantiprolif
peptid
ang
would
also
influenc
vasoconstrictiveprolif
effect
aceang
axi
part
vasoprotectiveantiprolif
axi
effect
control
fibrosi
structur
remodel
extrem
benefici
pulmonari
hypertens
activ
may
provid
improv
protect
revers
ischaemiainduc
neural
damag
thu
direct
activ
could
result
better
outcom
cardiovascular
diseas
addit
multifunct
enzym
mani
biolog
activ
substrat
effect
substrat
ang
ang
ii
may
hold
relev
treatment
cardiovascular
diseas
xnt
analogu
exist
mani
natur
plant
resourc
shown
variou
physiolog
function
use
resourc
search
vitro
activ
would
good
start
point
develop
plant
foodderiv
activ
agent
ongo
experi
would
character
activ
compar
ra
regulatori
drug
plantfoodderiv
bioactiv
appear
natur
safer
consum
part
daili
diet
bioactiv
food
sourc
may
result
much
lower
healthcar
cost
plantfoodderiv
ra
regul
could
appli
prevent
hypertens
initi
treatment
mildli
hypertens
individu
author
declar
conflict
interest
concern
articl
